📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Cost-effectiveness intervention thresholds for romosozumab and teriparatide in the treatment of osteoporosis in the UK. (2024)

First Author: Borgström F

Attributed to: Programme 3: Early development and risk of adult musculoskeletal disease funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s00198-024-07251-w

PubMed Identifier: 39365433

Publication URI: http://europepmc.org/abstract/MED/39365433

Type: Journal Article/Review

Volume: 35

Parent Publication: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

Issue: 12

ISSN: 0937-941X